指南与共识姑息放疗与转移瘤放疗物理与技术

从放射肿瘤学视角定义寡转移性疾病:ESTRO-ASTRO共识文件

Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document.
指南 / 共识 · Radiother Oncol · 2020-04-22

ESTRO与ASTRO召集委员会,通过系统文献综述与Delphi共识流程,确立寡转移性疾病(OMD)的放疗视角定义。共识认为OMD largely独立于原发肿瘤、转移部位及无病间期,可定义为1-5个转移灶、原发灶是否控制可选、但所有转移部位须可安全放疗。

要点

  • OMD可定义为1-5个转移灶,原发灶控制与否可选,所有转移灶须可安全放疗。
  • OMD largely独立于原发肿瘤类型、转移部位及无病间期长短。
  • 系统治疗诱导的OMD被识别为独立状态,需高分辨率影像确认。

核心结论

  • 基于现有数据,OMD可定义为1-5个转移灶,原发肿瘤是否控制为可选条件,但所有转移部位必须可安全接受根治性放疗。
  • OMD largely独立于原发肿瘤、转移部位及无病间期存在与否或长短,支持同步与异时性OMD。
  • 系统治疗诱导的OMD被识别为一种独立的OMD状态。

研究设计与样本

  • ESTRO与ASTRO召集委员会,在Medline、Embase和Cochrane进行聚焦根治性意图转移灶定向放疗(MDRT)的系统文献综述。
  • 采用Delphi流程进行共识意见形成,突出当前证据状态与现有文献局限性。

主要发现

  • 关于MDRT用于OMD的现有证据主要来自回顾性、单中心系列,患者纳入标准、OMD定义和报告结局存在显著异质性。
  • 在缺乏支持最大转移灶数目和器官数以及验证的分子生物标志物的临床数据情况下,共识支持以根治性意图对所有转移部位安全实施有临床意义放疗作为放疗背景下定义OMD的最低要求。
  • 高分辨率影像评估和确认OMD至关重要,包括有指征时的脑影像。

关键数值与推荐

  • OMD可定义为1-5个转移灶,原发肿瘤控制为可选条件,但所有转移部位必须可安全治疗。
  • 应报告最低共同终点如无进展生存和总生存、局部控制、毒性和生活质量;不常见终点如延迟系统治疗和费用也获认可。

临床怎么用

  • 放疗科在评估OMD时,应以所有转移部位可安全接受根治性意图放疗为最低前提。
  • 需使用高分辨率影像确认OMD,包括有指征时的脑影像。
  • 临床报告应包含无进展生存、总生存、局部控制、毒性和生活质量等最低共同终点。

局限性

  • 现有证据主要来自回顾性、单中心系列,患者纳入标准、OMD定义和报告结局存在显著异质性。
  • 缺乏支持最大转移灶数目和器官数以及验证的分子生物标志物的临床数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recognizing the rapidly increasing interest and evidence in using metastasis-directed radiotherapy (MDRT) for oligometastatic disease (OMD), ESTRO and ASTRO convened a committee to establish consensus regarding definitions of OMD and define gaps in current evidence. METHODS: A systematic literature review focused on curative intent MDRT was performed in Medline, Embase and Cochrane. Subsequent consensus opinion, using a Delphi process, highlighted the current state of evidence and the limitations in the available literature. RESULTS: Available evidence regarding the use of MDRT for OMD mostly derives from retrospective, single-centre series, with significant heterogeneity in patient inclusion criteria, definition of OMD, and outcomes reported. Consensus was reached that OMD is largely independent of primary tumour, metastatic location and the presence or length of a disease-free interval, supporting both synchronous and metachronous OMD. In the absence of clinical data supporting a maximum number of metastases and organs to define OMD, and of validated molecular biomarkers, consensus supported the ability to deliver safe and clinically meaningful radiotherapy with curative intent to all metastatic sites as a minimum requirement for defining OMD in the context of radiotherapy. Systemic therapy induced OMD was identified as a distinct state of OMD. High-resolution imaging to assess and confirm OMD is crucial, including brain imaging when indicated. Minimum common endpoints such as progression-free and overall survival, local control, toxicity and quality-of-life should be reported; uncommon endpoints as deferral of systemic therapy and cost were endorsed. CONCLUSION: While significant heterogeneity exists in the current OMD definitions in the literature, consensus was reached on multiple key questions. Based on available data, OMD can to date be defined as 1-5 metastatic lesions, a controlled primary tumor being optional, but where all metastatic sites must be safely treatable. Consistent definitions and reporting are warranted and encouraged in ongoing trials and reports generating further evidence to optimize patient benefits.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Lievens Y, Guckenberger M, Gomez D, et al. Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document. Radiother Oncol. 2020. PMID: 32388150. doi:10.1016/j.radonc.2020.04.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。